Australia - inglese - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - cisplatin is used in the treatment of certain types of cancer, for example ovarian cancer, testicular cancer, bladder cancer and head and neck cancer. cisplatin may be used in combination with other anti-cancer medicines.

Filippine - inglese - FDA (Food And Drug Administration)

global pharmatrade; distributor: global pharmatrade - mannitol - solution for intravenous infusion - 50g/250ml

Filippine - inglese - FDA (Food And Drug Administration)

genson distribution, inc.; distributor: genson distribution, inc. - mannitol - solution for intravenous infusion - 20% w/v

Filippine - inglese - FDA (Food And Drug Administration)

global pharmatrade; distributor: global pharmatrade - mannitol - solution for intravenous infusion - 200mg/ml (20% w/v)

Filippine - inglese - FDA (Food And Drug Administration)

global pharmatrade; distributor: global pharmatrade - mannitol - solution for intravenous infusion - 200mg/ml (20% w/v)

Filippine - inglese - FDA (Food And Drug Administration)

sahar international trading, inc.; distributor: sahar international trading, inc. - mannitol - solution for intravenous infusion - 20 mg/100 ml (20% w/v)

Stati Uniti - inglese - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously trea

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk - dexmedetomidine hydrochloride - solution for infusion - 100microgram/1ml

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk - dexmedetomidine hydrochloride - solution for infusion - 100microgram/1ml

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk - dexmedetomidine hydrochloride - solution for infusion - 100microgram/1ml